



Tumor Necrosis Factor Inhibitor Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-31	121	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Tumor Necrosis Factor Inhibitor Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Tumor Necrosis Factor Inhibitor Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Tumor Necrosis Factor Inhibitor Drug is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Tumor Necrosis Factor Inhibitor Drug is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Tumor Necrosis Factor Inhibitor Drug include UCB, Shanghai Pharmaceuticals Holding Co., Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Amgen Inc., AbbVie Inc. and PROBIOMED, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Tumor Necrosis Factor Inhibitor Drug market in terms of revenue (US\$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tumor Necrosis Factor Inhibitor Drug Market by Company

UCB

Shanghai Pharmaceuticals Holding Co., Ltd.

Johnson & Johnson

Novartis AG

Merck & Co., Inc.

Pfizer, Inc.

Amgen Inc.

AbbVie Inc.

PROBIOMED

LEO Pharma

EPIRUS Biopharmaceuticals

CASI Pharmaceuticals

Tumor Necrosis Factor Inhibitor Drug Segment by Type

Humira

Enbrel

Biosimilars

Cimzia

Simponi

Remicade

Tumor Necrosis Factor Inhibitor Drug Segment by Application

Juvenile Idiopathic Arthritis

Psoriatic Arthritis

Rheumatoid Arthritis

Ulcerative Colitis

Crohn's Disease

Others

Tumor Necrosis Factor Inhibitor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Inhibitor Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Tumor Necrosis Factor Inhibitor Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Tumor Necrosis Factor Inhibitor Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Tumor Necrosis Factor Inhibitor Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Tumor Necrosis Factor Inhibitor Drug Market Size (2021-2032)
 - 2.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales (2021-2032)
 - 2.2.3 Global Tumor Necrosis Factor Inhibitor Drug Market Average Price (2021-2032)
- 2.3 Tumor Necrosis Factor Inhibitor Drug by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Humira
 - 2.3.3 Enbrel
 - 2.3.4 Biosimilars
 - 2.3.5 Cimzia
 - 2.3.6 Simponi
 - 2.3.7 Remicade
- 2.4 Tumor Necrosis Factor Inhibitor Drug by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Juvenile Idiopathic Arthritis
 - 2.4.3 Psoriatic Arthritis
 - 2.4.4 Rheumatoid Arthritis
 - 2.4.5 Ulcerative Colitis
 - 2.4.6 Crohn's Disease
 - 2.4.7 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Tumor Necrosis Factor Inhibitor Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Tumor Necrosis Factor Inhibitor Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Tumor Necrosis Factor Inhibitor Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Product Type & Application
- 3.8 Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Established Date
- 3.9 Global Tumor Necrosis Factor Inhibitor Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 UCB

- 4.1.1 UCB Company Information
- 4.1.2 UCB Business Overview
- 4.1.3 UCB Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 UCB Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- 4.1.5 UCB Recent Developments
- 4.2 Shanghai Pharmaceuticals Holding Co., Ltd.
 - 4.2.1 Shanghai Pharmaceuticals Holding Co., Ltd. Company Information
 - 4.2.2 Shanghai Pharmaceuticals Holding Co., Ltd. Business Overview
 - 4.2.3 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
 - 4.2.5 Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments
- 4.3 Johnson & Johnson
 - 4.3.1 Johnson & Johnson Company Information
 - 4.3.2 Johnson & Johnson Business Overview
 - 4.3.3 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Portfolio
 - 4.3.5 Johnson & Johnson Recent Developments
- 4.4 Novartis AG
 - 4.4.1 Novartis AG Company Information
 - 4.4.2 Novartis AG Business Overview
 - 4.4.3 Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Portfolio
 - 4.4.5 Novartis AG Recent Developments
- 4.5 Merck & Co., Inc.
 - 4.5.1 Merck & Co., Inc. Company Information
 - 4.5.2 Merck & Co., Inc. Business Overview
 - 4.5.3 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
 - 4.5.5 Merck & Co., Inc. Recent Developments
- 4.6 Pfizer, Inc.
 - 4.6.1 Pfizer, Inc. Company Information
 - 4.6.2 Pfizer, Inc. Business Overview
 - 4.6.3 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
 - 4.6.5 Pfizer, Inc. Recent Developments
- 4.7 Amgen Inc.
 - 4.7.1 Amgen Inc. Company Information
 - 4.7.2 Amgen Inc. Business Overview
 - 4.7.3 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
 - 4.7.5 Amgen Inc. Recent Developments
- 4.8 AbbVie Inc.
 - 4.8.1 AbbVie Inc. Company Information
 - 4.8.2 AbbVie Inc. Business Overview
 - 4.8.3 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
 - 4.8.5 AbbVie Inc. Recent Developments

4.9 PROBIOMED

4.9.1 PROBIOMED Company Information

4.9.2 PROBIOMED Business Overview

4.9.3 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)

4.9.4 PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Portfolio

4.9.5 PROBIOMED Recent Developments

4.10 LEO Pharma

4.10.1 LEO Pharma Company Information

4.10.2 LEO Pharma Business Overview

4.10.3 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)

4.10.4 LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Portfolio

4.10.5 LEO Pharma Recent Developments

4.11 EPIRUS Biopharmaceuticals

4.11.1 EPIRUS Biopharmaceuticals Company Information

4.11.2 EPIRUS Biopharmaceuticals Business Overview

4.11.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)

4.11.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio

4.11.5 EPIRUS Biopharmaceuticals Recent Developments

4.12 CASI Pharmaceuticals

4.12.1 CASI Pharmaceuticals Company Information

4.12.2 CASI Pharmaceuticals Business Overview

4.12.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales, Revenue and Gross Margin (2021-2026)

4.12.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio

4.12.5 CASI Pharmaceuticals Recent Developments

5 Global Tumor Necrosis Factor Inhibitor Drug Market Scenario by Region

5.1 Global Tumor Necrosis Factor Inhibitor Drug Market Size by Region: 2021 VS 2025 VS 2032

5.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region: 2021-2032

5.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region: 2021-2026

5.2.2 Global Tumor Necrosis Factor Inhibitor Drug Sales by Region: 2027-2032

5.3 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region: 2021-2032

5.3.1 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region: 2021-2026

5.3.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region: 2027-2032

5.4 North America Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country

5.4.1 North America Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2021 VS 2025 VS 2032

5.4.2 North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)

5.4.3 North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2032)

5.4.4 United States

5.4.5 Canada

5.5 Europe Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country

5.5.1 Europe Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2021 VS 2025 VS 2032

5.5.2 Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)

5.5.3 Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2032)

5.5.4 Germany

5.5.5 France

5.5.6 U.K.

5.5.7 Italy

5.5.8 Netherlands

5.5.9 Nordic Countries

5.6 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country

5.6.1 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2021 VS 2025 VS 2032

5.6.2 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)

5.6.3 Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2032)

5.6.4 China

5.6.5 Japan

5.6.6 South Korea

5.6.7 India

5.6.8 Australia

5.6.9 China Taiwan

5.6.10 Southeast Asia

5.7 South America Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country

5.7.1 South America Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2021 VS 2025 VS 2032

5.7.2 South America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)

5.7.3 South America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2032)

5.7.4 Mexico

5.7.5 Brazil

5.7.6 Argentina

5.8 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Market Facts & Figures by Country

5.8.1 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Market Size by Country: 2021 VS 2025 VS 2032

5.8.2 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2032)

5.8.3 Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2032)

5.8.4 Turkey

5.8.5 Saudi Arabia

5.8.6 UAE

6 Segment by Type

6.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2021-2032)

6.1.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2021-2032) & (K Units)

6.1.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2021-2032)

6.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2021-2032)

6.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2021-2032) & (US\$ Million)

6.2.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2021-2032)

6.3 Global Tumor Necrosis Factor Inhibitor Drug Price by Type (2021-2032)

7 Segment by Application

7.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2021-2032)

7.1.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2021-2032) & (K Units)

7.1.2 Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2021-2032)

7.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2021-2032)

7.2.1 Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2021-2032)

7.3 Global Tumor Necrosis Factor Inhibitor Drug Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Tumor Necrosis Factor Inhibitor Drug Value Chain Analysis

8.1.1 Tumor Necrosis Factor Inhibitor Drug Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Tumor Necrosis Factor Inhibitor Drug Production Mode & Process

8.2 Tumor Necrosis Factor Inhibitor Drug Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Tumor Necrosis Factor Inhibitor Drug Distributors

8.2.3 Tumor Necrosis Factor Inhibitor Drug Customers

9 Global Tumor Necrosis Factor Inhibitor Drug Analyzing Market Dynamics

9.1 Tumor Necrosis Factor Inhibitor Drug Industry Trends

9.2 Tumor Necrosis Factor Inhibitor Drug Industry Drivers

9.3 Tumor Necrosis Factor Inhibitor Drug Industry Opportunities and Challenges

9.4 Tumor Necrosis Factor Inhibitor Drug Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Tumor Necrosis Factor Inhibitor Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Tumor Necrosis Factor Inhibitor Drug Sales (K Units) of Manufacturers (2021-2026)
- Table 7: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Tumor Necrosis Factor Inhibitor Drug Revenue of Manufacturers (2021-2026)
- Table 9: Global Tumor Necrosis Factor Inhibitor Drug Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Tumor Necrosis Factor Inhibitor Drug Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Tumor Necrosis Factor Inhibitor Drug Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Product Type & Application
- Table 14: Global Tumor Necrosis Factor Inhibitor Drug Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Tumor Necrosis Factor Inhibitor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: UCB Company Information
- Table 19: UCB Business Overview
- Table 20: UCB Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: UCB Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 22: UCB Recent Developments
- Table 23: Shanghai Pharmaceuticals Holding Co., Ltd. Company Information
- Table 24: Shanghai Pharmaceuticals Holding Co., Ltd. Business Overview
- Table 25: Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Shanghai Pharmaceuticals Holding Co., Ltd. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 27: Shanghai Pharmaceuticals Holding Co., Ltd. Recent Developments
- Table 28: Johnson & Johnson Company Information
- Table 29: Johnson & Johnson Business Overview
- Table 30: Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: Johnson & Johnson Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 32: Johnson & Johnson Recent Developments
- Table 33: Novartis AG Company Information
- Table 34: Novartis AG Business Overview
- Table 35: Novartis AG Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: Novartis AG Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 37: Novartis AG Recent Developments
- Table 38: Merck & Co., Inc. Company Information
- Table 39: Merck & Co., Inc. Business Overview
- Table 40: Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Merck & Co., Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 42: Merck & Co., Inc. Recent Developments
- Table 43: Pfizer, Inc. Company Information
- Table 44: Pfizer, Inc. Business Overview
- Table 45: Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 46: Pfizer, Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 47: Pfizer, Inc. Recent Developments

- Table 48: Amgen Inc. Company Information
- Table 49: Amgen Inc. Business Overview
- Table 50: Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 51: Amgen Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 52: Amgen Inc. Recent Developments
- Table 53: AbbVie Inc. Company Information
- Table 54: AbbVie Inc. Business Overview
- Table 55: AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 56: AbbVie Inc. Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 57: AbbVie Inc. Recent Developments
- Table 58: PROBIOMED Company Information
- Table 59: PROBIOMED Business Overview
- Table 60: PROBIOMED Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 61: PROBIOMED Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 62: PROBIOMED Recent Developments
- Table 63: LEO Pharma Company Information
- Table 64: LEO Pharma Business Overview
- Table 65: LEO Pharma Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 66: LEO Pharma Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 67: LEO Pharma Recent Developments
- Table 68: EPIRUS Biopharmaceuticals Company Information
- Table 69: EPIRUS Biopharmaceuticals Business Overview
- Table 70: EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 71: EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 72: EPIRUS Biopharmaceuticals Recent Developments
- Table 73: CASI Pharmaceuticals Company Information
- Table 74: CASI Pharmaceuticals Business Overview
- Table 75: CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Sales (K Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 76: CASI Pharmaceuticals Tumor Necrosis Factor Inhibitor Drug Product Portfolio
- Table 77: CASI Pharmaceuticals Recent Developments
- Table 78: Global Tumor Necrosis Factor Inhibitor Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 79: Global Tumor Necrosis Factor Inhibitor Drug Sales by Region (2021-2026) & (K Units)
- Table 80: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2021-2026)
- Table 81: Global Tumor Necrosis Factor Inhibitor Drug Sales by Region (2027-2032) & (K Units)
- Table 82: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Region (2027-2032)
- Table 83: Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2021-2026) & (US\$ Million)
- Table 84: Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2021-2026)
- Table 85: Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region (2027-2032) & (US\$ Million)
- Table 86: Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Region (2027-2032)
- Table 87: North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 88: North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units)
- Table 89: North America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units)
- Table 90: North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 91: North America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 92: Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 93: Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units)
- Table 94: Europe Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units)
- Table 95: Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 96: Europe Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 97: Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 98: Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units)
- Table 99: Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units)
- Table 100: Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 101: Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 102: South America Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 103: South America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units)
- Table 104: South America Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units)
- Table 105: South America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 106: South America Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2027-2032) & (US\$ Million)

- Table 107: Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 108: Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2021-2026) & (K Units)
- Table 109: Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales by Country (2027-2032) & (K Units)
- Table 110: Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 111: Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 112: Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2021-2026) & (K Units)
- Table 113: Global Tumor Necrosis Factor Inhibitor Drug Sales by Type (2027-2032) & (K Units)
- Table 114: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2021-2026)
- Table 115: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2027-2032)
- Table 116: Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2021-2026) & (US\$ Million)
- Table 117: Global Tumor Necrosis Factor Inhibitor Drug Revenue by Type (2027-2032) & (US\$ Million)
- Table 118: Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2021-2026)
- Table 119: Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2027-2032)
- Table 120: Global Tumor Necrosis Factor Inhibitor Drug Price by Type (2021-2026) & (US\$/Unit)
- Table 121: Global Tumor Necrosis Factor Inhibitor Drug Price by Type (2027-2032) & (US\$/Unit)
- Table 122: Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2021-2026) & (K Units)
- Table 123: Global Tumor Necrosis Factor Inhibitor Drug Sales by Application (2027-2032) & (K Units)
- Table 124: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2021-2026)
- Table 125: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2027-2032)
- Table 126: Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2021-2026) & (US\$ Million)
- Table 127: Global Tumor Necrosis Factor Inhibitor Drug Revenue by Application (2027-2032) & (US\$ Million)
- Table 128: Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2021-2026)
- Table 129: Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2027-2032)
- Table 130: Global Tumor Necrosis Factor Inhibitor Drug Price by Application (2021-2026) & (US\$/Unit)
- Table 131: Global Tumor Necrosis Factor Inhibitor Drug Price by Application (2027-2032) & (US\$/Unit)
- Table 132: Key Raw Materials
- Table 133: Raw Materials Key Suppliers
- Table 134: Tumor Necrosis Factor Inhibitor Drug Distributors List
- Table 135: Tumor Necrosis Factor Inhibitor Drug Customers List
- Table 136: Tumor Necrosis Factor Inhibitor Drug Industry Trends
- Table 137: Tumor Necrosis Factor Inhibitor Drug Industry Drivers
- Table 138: Tumor Necrosis Factor Inhibitor Drug Industry Restraints
- Table 139: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Tumor Necrosis Factor Inhibitor Drug Product Image
- Figure 5: Global Tumor Necrosis Factor Inhibitor Drug Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Tumor Necrosis Factor Inhibitor Drug Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Tumor Necrosis Factor Inhibitor Drug Sales (2021-2032) & (K Units)
- Figure 8: Global Tumor Necrosis Factor Inhibitor Drug Average Price (US\$/Unit) & (2021-2032)
- Figure 9: Humira Product Image
- Figure 10: Enbrel Product Image
- Figure 11: Biosimilars Product Image
- Figure 12: Cimzia Product Image
- Figure 13: Simponi Product Image
- Figure 14: Remicade Product Image
- Figure 15: Juvenile Idiopathic Arthritis Product Image
- Figure 16: Psoriatic Arthritis Product Image
- Figure 17: Rheumatoid Arthritis Product Image
- Figure 18: Ulcerative Colitis Product Image
- Figure 19: Crohn's Disease Product Image
- Figure 20: Others Product Image
- Figure 21: Global Tumor Necrosis Factor Inhibitor Drug Revenue Share by Manufacturers in 2025
- Figure 22: Global Manufacturers of Tumor Necrosis Factor Inhibitor Drug, Manufacturing Sites & Headquarters
- Figure 23: Global Top 5 and 10 Tumor Necrosis Factor Inhibitor Drug Players Market Share by Revenue in 2025
- Figure 24: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 25: Global Tumor Necrosis Factor Inhibitor Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 26: Global Tumor Necrosis Factor Inhibitor Drug Sales by Region in 2025
- Figure 27: Global Tumor Necrosis Factor Inhibitor Drug Revenue by Region in 2025

- Figure 28: North America Tumor Necrosis Factor Inhibitor Drug Market Size by Country in 2025
- Figure 29: North America Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032)
- Figure 30: North America Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2021-2032)
- Figure 31: United States Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 32: Canada Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: Europe Tumor Necrosis Factor Inhibitor Drug Market Size by Country in 2025
- Figure 34: Europe Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032)
- Figure 35: Europe Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2021-2032)
- Figure 36: Germany Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: France Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: U.K. Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Italy Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Netherlands Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Nordic Countries Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Asia Pacific Tumor Necrosis Factor Inhibitor Drug Market Size by Country in 2025
- Figure 43: Asia Pacific Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032)
- Figure 44: Asia Pacific Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2021-2032)
- Figure 45: China Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: Japan Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: South Korea Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: India Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Australia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: China Taiwan Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Southeast Asia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Southeast Asia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: South America Tumor Necrosis Factor Inhibitor Drug Market Size by Country in 2025
- Figure 54: South America Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032)
- Figure 55: South America Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2021-2032)
- Figure 56: Mexico Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Brazil Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Argentina Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Market Size by Country in 2025
- Figure 60: Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Country (2021-2032)
- Figure 61: Middle East and Africa Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Country (2021-2032)
- Figure 62: Turkey Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: Saudi Arabia Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: UAE Tumor Necrosis Factor Inhibitor Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Type (2021-2032)
- Figure 66: Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Type (2021-2032)
- Figure 67: Global Tumor Necrosis Factor Inhibitor Drug Price (US\$/Unit) by Type (2021-2032)
- Figure 68: Global Tumor Necrosis Factor Inhibitor Drug Sales Market Share by Application (2021-2032)
- Figure 69: Global Tumor Necrosis Factor Inhibitor Drug Revenue Market Share by Application (2021-2032)
- Figure 70: Global Tumor Necrosis Factor Inhibitor Drug Price (US\$/Unit) by Application (2021-2032)
- Figure 71: Tumor Necrosis Factor Inhibitor Drug Value Chain
- Figure 72: Tumor Necrosis Factor Inhibitor Drug Production Mode & Process
- Figure 73: Direct Comparison with Distribution Share
- Figure 74: Distributors Profiles
- Figure 75: Tumor Necrosis Factor Inhibitor Drug Industry Opportunities and Challenges